Giovanni Riva, Vincenzo Nasillo, Anna Maria Ottomano, Giuliano Bergonzini, Ambra Paolini, Fabio Forghieri, Beatrice Lusenti, Patrizia Barozzi, Ivana Lagreca, Stefania Fiorcari, Silvia Martinelli, Rossana Maffei, Roberto Marasca, Leonardo Potenza, Patrizia Comoli, Rossella Manfredini, Enrico Tagliafico, Tommaso Trenti, Mario Luppi
Along with the evolution of immunophenotypic and molecular diagnostics, the assessment of Minimal Residual Disease (MRD) has progressively become a keystone in the clinical management of hematologic malignancies, enabling valuable post-therapy risk stratifications and guiding risk-adapted therapeutic approaches. However, specific prognostic values of MRD in different hematological settings, as well as its appropriate clinical uses (basically, when to measure it and how to deal with different MRD levels), still need further investigations, aiming to improve standardization and harmonization of MRD monitoring protocols and MRD-driven therapeutic strategies...
September 12, 2021: Cancers